Rhythm Pharmaceuticals Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Rhythm Pharmaceuticals (RYTM) Tops Q3 EPS by 3c
November 1, 2019 8:36 AM EDTRhythm Pharmaceuticals (NASDAQ: RYTM) reported Q3 EPS of ($1.04), $0.03 better than the analyst estimate of ($1.07).
Announced Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency ObesitiesAdded Four New MC4R Pathway Obesity Indications to Phase 2 Basket Study and Enrolling Patients --Announced Genetic Sequencing Data Supporting Ultra-Rarity of POMC and LEPR Deficiency Obesities and Suggesting U.S. Prevalence for Four New Basket Indications of > 60,000Successfully Completed $172.5 Million Public... More